Titre
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
Type
article
Institution
Externe
Périodique
Auteur(s)
Marzolini, C.
Auteure/Auteur
Sabin, C.
Auteure/Auteur
Raffi, F.
Auteure/Auteur
Siccardi, M.
Auteure/Auteur
Mussini, C.
Auteure/Auteur
Launay, O.
Auteure/Auteur
Burger, D.
Auteure/Auteur
Roca, B.
Auteure/Auteur
Fehr, J.
Auteure/Auteur
Bonora, S.
Auteure/Auteur
Mocroft, A.
Auteure/Auteur
Obel, N.
Auteure/Auteur
Dauchy, F.A.
Auteure/Auteur
Zangerle, R.
Auteure/Auteur
Gogos, C.
Auteure/Auteur
Gianotti, N.
Auteure/Auteur
Ammassari, A.
Auteure/Auteur
Torti, C.
Auteure/Auteur
Ghosn, J.
Auteure/Auteur
Chêne, G.
Auteure/Auteur
Grarup, J.
Auteure/Auteur
Battegay, M.
Auteure/Auteur
Contributrices/contributeurs
Marzolini, C.
Sabin, C.
Raffi, F.
Siccardi, M.
Mussini, C.
Launay, O.
Burger, D.
Roca, B.
Fehr, J.
Bonora, S.
Mocroft, A.
Obel, N.
Dauchy, F.A.
Zangerle, R.
Gogos, C.
Gianotti, N.
Ammassari, A.
Torti, C.
Ghosn, J.
Chêne, G.
Grarup, J.
Battegay, M.
Zangerle, R.
Touloumi, G.
Warszawski, J.
Meyer, L.
Dabis, F.
Krause, M.M.
Ghosn, J.
Leport, C.
Reiss, P.
Wit, F.
Prins, M.
Bucher, H.
Sabin, C.
Gibb, D.
Fätkenheuer, G.
Del Amo, J.
Obel, N.
Thorne, C.
Mocroft, A.
Kirk, O.
Stephan, C.
Perez-Hoyos, S.
Hamouda, O.
Bartmeyer, B.
Chkhartishvili, N.
Noguera-Julian, A.
Antinori, A.
d'Arminio Monforte, A.
Brockmeyer, N.
Prieto, L.
Conejo, P.R.
Soriano-Arandes, A.
Battegay, M.
Rauch, A.
Mussini, C.
Tookey, P.
Casabona, J.
Miro, J.M.
Castagna, A.
Konopnick, D.
Goetghebuer, T.
Torti, C.
Teira, R.
Garrido, M.
Haerry, D.
de Wit, S.
Casabona, J.
Costagliola, D.
d'Arminio-Monforte, A.
Battegay, M.
del Amo, J.
Mocroft, A.
Raben, D.
Chêne, G.
Judd, A.
Conejo, P.R.
Barger, D.
Colin, C.
Schwimmer, C.
Termote, M.
Wittkop, L.
Campbell, M.
Friis-Moller, N.
Kjaer, J.
Raben, D.
Brandt, R.S.
Battegay, M.
Bohlius, J.
Bouteloup, V.
Bucher, H.
Cozzi-Lepri, A.
Dabis, F.
d'Arminio Monforte, A.
del Amo, J.
Dorrucci, M.
Egger, M.
Furrer, H.
Judd, A.
Kirk, O.
Lambotte, O.
Lodi, S.
Matheron, S.
Meyer, L.
Miro, J.
Mocroft, A.
Monge, S.
Nakagawa, F.
Paredes, R.
Phillips, A.
Puoti, M.
Sabin, C.
Smit, C.
Sterne, J.
Thiebaut, R.
Thorne, C.
Torti, C.
Touloumi, G.
van der Valk, M.
Wittkop, L.
Wyss, N.
Groupes de travail
Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
Liens vers les personnes
ISSN
1473-5571
Statut éditorial
Publié
Date de publication
2015-01-14
Volume
29
Numéro
2
Première page
193
Dernière page/numéro d’article
200
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
The prevalence of overweight and obesity is increasing among HIV-infected patients. Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved. We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients.
Observational European cohort collaboration study.
Eligible patients were antiretroviral-naïve with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load (<50 copies/ml) after treatment initiation, and time to viral load rebound (two consecutive viral load >50 copies/ml) after initial suppression over 5 years of follow-up. Recovery of CD4 cell count was evaluated 6 and 12 months after EFV initiation. Analyses were stratified by weight (kg) group (I - <55; II - >55, <80 (reference); III - >80, <85; IV - >85, <90; V - >90, <95; VI - >95).
The study included 19,968 patients, of whom 9.1, 68.3, 9.1, 5.8, 3.5, and 4.3% were in weight groups I-VI, respectively. Overall, 81.1% patients attained virological suppression, of whom 34.1% subsequently experienced viral load rebound. After multiple adjustments, no statistical difference was observed in time to undetectable viral load and virological rebound for heavier individuals compared to their normal-weight counterparts. Although heaviest individuals had significantly higher CD4 cell count at baseline, CD4 cell recovery at 6 and 12 months after EFV initiation was comparable to normal-weight individuals.
Virological and immunological responses to initial EFV-containing regimens were not impaired in heavy individuals, suggesting that the standard 600 mg EFV dosage is appropriate across a wide weight range.
Observational European cohort collaboration study.
Eligible patients were antiretroviral-naïve with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load (<50 copies/ml) after treatment initiation, and time to viral load rebound (two consecutive viral load >50 copies/ml) after initial suppression over 5 years of follow-up. Recovery of CD4 cell count was evaluated 6 and 12 months after EFV initiation. Analyses were stratified by weight (kg) group (I - <55; II - >55, <80 (reference); III - >80, <85; IV - >85, <90; V - >90, <95; VI - >95).
The study included 19,968 patients, of whom 9.1, 68.3, 9.1, 5.8, 3.5, and 4.3% were in weight groups I-VI, respectively. Overall, 81.1% patients attained virological suppression, of whom 34.1% subsequently experienced viral load rebound. After multiple adjustments, no statistical difference was observed in time to undetectable viral load and virological rebound for heavier individuals compared to their normal-weight counterparts. Although heaviest individuals had significantly higher CD4 cell count at baseline, CD4 cell recovery at 6 and 12 months after EFV initiation was comparable to normal-weight individuals.
Virological and immunological responses to initial EFV-containing regimens were not impaired in heavy individuals, suggesting that the standard 600 mg EFV dosage is appropriate across a wide weight range.
PID Serval
serval:BIB_7EACCBC2761B
PMID
Open Access
Oui
Date de création
2023-08-25T04:17:22.476Z
Date de création dans IRIS
2025-05-20T23:05:40Z